<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of refractory cutaneous dermatomyositis in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of refractory cutaneous dermatomyositis in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of refractory cutaneous dermatomyositis in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ruth Ann Vleugels, MD, MPH, MBA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Callen, MD, FACP, FAAD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 09, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H19331632">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Classic dermatomyositis (DM) is an idiopathic inflammatory myopathy that most commonly presents with progressive, symmetric, proximal muscle weakness and a group of characteristic cutaneous findings. The cutaneous manifestations of DM may also develop in the absence of detectable muscle disease and can persist after the successful treatment of DM-associated myositis. (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults"
         </a>
         .)
        </p>
        <p>
         Skin lesions of DM are often resistant to photoprotection and topical therapies alone, necessitating the initiation of systemic therapy  (
         <a class="graphic graphic_algorithm graphicRef119738" href="/z/d/graphic/119738.html" rel="external">
          algorithm 1
         </a>
         ). Patients who fail to respond to antimalarials and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , or who relapse during therapy with these agents, require more aggressive immunosuppressive or immunomodulatory drugs. (See
         <a class="medical medical_review" href="/z/d/html/13771.html" rel="external">
          "Cutaneous dermatomyositis in adults: Overview and initial management"
         </a>
         .)
        </p>
        <p>
         The management of patients with refractory cutaneous DM will be discussed here. The initial treatment of cutaneous DM, as well as the clinical manifestations, diagnosis, and management of the extracutaneous manifestations of DM and juvenile DM, are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/13771.html" rel="external">
          "Cutaneous dermatomyositis in adults: Overview and initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5160.html" rel="external">
          "Initial treatment of dermatomyositis and polymyositis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5133.html" rel="external">
          "Treatment of recurrent and resistant dermatomyositis and polymyositis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6419.html" rel="external">
          "Juvenile dermatomyositis and other idiopathic inflammatory myopathies: Epidemiology, pathogenesis, and clinical manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6418.html" rel="external">
          "Juvenile dermatomyositis and polymyositis: Treatment, complications, and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19331639">
         <span class="h1">
          APPROACH TO REFRACTORY DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         DM is associated with characteristic cutaneous findings, most notably a pruritic, violaceous to erythematous eruption involving the scalp, face, neck, upper trunk, arms, and dorsal hands  (
         <a class="graphic graphic_picture graphicRef56879 graphicRef68649 graphicRef54230 graphicRef77822 graphicRef79924 graphicRef63383" href="/z/d/graphic/56879.html" rel="external">
          picture 1A-F
         </a>
         ). Pruritus associated with DM can be severe, leading to significant detrimental effects on patient quality of life. (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults", section on 'Skin findings in dermatomyositis'
         </a>
         .)
        </p>
        <p>
         For a subset of patients with skin manifestations of DM, trials of multiple therapies (in combination or sequentially) are required to identify the treatment regimen that produces satisfactory disease control. Because many patients fail to improve adequately with photoprotection, antipruritics, and topical corticosteroids or topical calcineurin inhibitors, the addition of systemic antimalarials or
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         is often necessary. Patients who fail to respond to these conventional interventions or who relapse after an initial response have refractory disease and require the initiation of more aggressive therapies  (
         <a class="graphic graphic_algorithm graphicRef119738" href="/z/d/graphic/119738.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/13771.html" rel="external">
          "Cutaneous dermatomyositis in adults: Overview and initial management", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         Calcinosis cutis is a cutaneous complication of DM that also can be refractory to treatment. (See
         <a class="local">
          'Calcinosis cutis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H676881">
         <span class="h2">
          Choice of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although a wide variety of immunomodulatory and immunosuppressive medications have been used in the treatment of refractory cutaneous DM, few studies have investigated the efficacy and safety of these agents in patients with cutaneous DM.
        </p>
        <p>
         Intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF) are our preferred treatments for DM refractory to conventional therapy (photoprotection, topical agents, antimalarials, and/or
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         )  (
         <a class="graphic graphic_algorithm graphicRef119738" href="/z/d/graphic/119738.html" rel="external">
          algorithm 1
         </a>
         ). Selection of these agents is based upon evidence that suggests efficacy and the knowledge that these are generally well-tolerated therapies. Although comparative studies have not been performed, clinicians with expertise in DM generally consider IVIG the most effective treatment and treatment of choice. However, the need for intravenous administration and the high cost of IVIG limit use of this agent in some patients. (See
         <a class="local">
          'Intravenous immune globulin'
         </a>
         below and
         <a class="local">
          'Mycophenolate mofetil'
         </a>
         below.)
        </p>
        <p>
         Additional treatments for refractory cutaneous DM include systemic immunosuppressants (eg,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         , Janus kinase [JAK] inhibitors, and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ),
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         , and
         <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">
          apremilast
         </a>
         . Due to limited or conflicting evidence in support of the efficacy of these agents and the risks for serious adverse effects associated with some of these drugs, we generally reserve the use of these agents for patients who have failed or who are poor candidates for
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         and MMF. The need for treatment of concomitant refractory muscle disease can also influence the choice of therapy. (See
         <a class="local">
          'Other therapies'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5133.html" rel="external">
          "Treatment of recurrent and resistant dermatomyositis and polymyositis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2918044533">
         <span class="h1">
          PRIMARY THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF) are our treatments of choice for refractory cutaneous DM  (
         <a class="graphic graphic_algorithm graphicRef119738" href="/z/d/graphic/119738.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H19331646">
         <span class="h2">
          Intravenous immune globulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         is a product derived from pooled donor plasma that contains numerous immunoregulatory substances. IVIG has been used successfully for refractory extracutaneous manifestations of DM and appears to be beneficial in patients with cutaneous manifestations of DM who have failed to respond adequately to other therapies. (See
         <a class="medical medical_review" href="/z/d/html/6418.html" rel="external">
          "Juvenile dermatomyositis and polymyositis: Treatment, complications, and prognosis", section on 'Intravenous immune globulin'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5133.html" rel="external">
          "Treatment of recurrent and resistant dermatomyositis and polymyositis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2345428">
         <span class="h3">
          Administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         In clinical practice, patients are usually treated
         <strong>
          monthly
         </strong>
         with 2 g/kg of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         given as infusions of 1 g/kg per day on two consecutive days every four weeks. Of note, in patients who develop intolerable side effects to this dosing schedule, the daily doses can be given two weeks apart (1 g/kg per day administered every two weeks), which is a frequently used dosing schedule for IVIG in children.
        </p>
        <p>
         Clinical improvement is expected within two to three months, but the full benefit may not be realized for six months. Given the high cost of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , the interval between treatments is typically progressively lengthened once the patient has achieved a complete or near complete clinical response (eg, in the traditional dosing schedule, adjusted to every five weeks, then every six weeks, etc). Relapse may occur upon treatment discontinuation; continued treatment may be necessary to maintain improvement.
        </p>
        <p class="headingAnchor" id="H3653229753">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Improvement in cutaneous DM has been reported in randomized trials designed to evaluate the efficacy of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         for muscle disease in DM [
         <a href="#rid1">
          1,2
         </a>
         ]. In the largest trial, 95 patients with DM were randomly assigned to IVIG (2 g/kg body weight) or placebo given every 4 weeks for 16 weeks [
         <a href="#rid2">
          2
         </a>
         ]. Treatment with IVIG was associated with a greater likelihood of at least minimal improvement in DM as defined by the change in the total improvement score at week 16 (79 percent in the IVIG group and 44 percent in the placebo group achieved minimal improvement). Assessment of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) total activity score also showed greater improvement in cutaneous disease in the IVIG group, with a mean change of -9.4 (95% CI -12.5 to -6.2) in the IVIG group compared with -1.2 (95% CI 3.3-1.0) in the placebo group.
        </p>
        <p>
         Retrospective studies, case reports, and case series offer additional support for the use of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         in refractory DM [
         <a href="#rid3">
          3-7
         </a>
         ]. Benefit from low-dose IVIG has been reported; in one woman with cutaneous manifestations of DM refractory to systemic glucocorticoids, five-day courses of IVIG (0.1 g/kg per day) given twice over the course of two weeks led to clinical improvement [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2345615">
         <span class="h3">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adverse effects of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         include hypersensitivity reactions, headaches, vasculitis, aseptic meningitis, renal failure, myocardial infarction, and thrombosis. (See
         <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">
          "Intravenous immune globulin: Adverse effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3360676949">
         <span class="h2">
          Mycophenolate mofetil
         </span>
         <span class="headingEndMark">
          —
         </span>
         MMF is an immunosuppressive agent that reversibly inhibits inosine monophosphate dehydrogenase, an enzyme required for de novo purine synthesis. The dependency of T and B lymphocytes on this pathway for the production of DNA and RNA is responsible for the selective immunosuppressive properties of MMF. MMF is used for the treatment of myositis in DM, and the drug also appears to be beneficial for skin disease. (See
         <a class="medical medical_review" href="/z/d/html/5133.html" rel="external">
          "Treatment of recurrent and resistant dermatomyositis and polymyositis in adults", section on 'Mycophenolate mofetil'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2277056344">
         <span class="h3">
          Administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         MMF is typically given as 2 to 3 g per day in two divided doses. Patients are typically started on 500 mg twice daily for two weeks, followed by laboratory tests and clinical assessment to confirm tolerance of the medication. The dose is then titrated to 1 g given twice daily and, if tolerated, to 1.5 g twice daily in many patients. Improvement in skin disease is expected within two to three months of treatment. If the response is poor after three months, we transition patients to other treatments.
        </p>
        <p>
         Given the relatively slow onset of action of MMF, overlapping treatment may reduce the risk for disease flares while awaiting the drug's onset of action and during titration of the MMF. In patients who are transitioning from
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         to MMF due to an inadequate response to methotrexate, we often continue methotrexate at a reduced dose (usually 10 to 15 mg per week) for several weeks to several months after starting MMF. Lowering the dose of methotrexate is intended to reduce cumulative immunosuppressive effects. In most patients, we taper and eventually discontinue methotrexate once clinical improvement is noted. However, in patients with particularly refractory disease, we may continue 10 to 15 mg per week of methotrexate in conjunction with MMF, with close monitoring for laboratory abnormalities and for infection. (See
         <a class="medical medical_review" href="/z/d/html/13771.html" rel="external">
          "Cutaneous dermatomyositis in adults: Overview and initial management", section on 'Methotrexate'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3583154848">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of MMF for the cutaneous manifestations of DM is supported by uncontrolled studies and a case series [
         <a href="#rid8">
          8-11
         </a>
         ]. A prospective cohort study of 74 patients with moderate to severe cutaneous DM managed with various therapies found an association between treatment with MMF and clinical remission [
         <a href="#rid8">
          8
         </a>
         ]. Furthermore, this study demonstrated that the majority of patients who achieved clinical remission with MMF were treated with 1.5 g twice daily, suggesting that higher doses may be required for effective treatment of DM skin disease.
        </p>
        <p>
         In a retrospective study of 12 patients with cutaneous DM that was refractory to other systemic drugs, MMF given alone or as an adjunctive therapy resulted in improvement in 10 patients (83 percent) [
         <a href="#rid11">
          11
         </a>
         ]. Most responses occurred within four to eight weeks, and all responses were attained at doses of 2 to 3 g per day. MMF also was effective in a series of four patients with skin lesions of DM that failed to respond to systemic glucocorticoids,
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         , and/or
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1371501223">
         <span class="h3">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         MMF has a favorable toxicity profile when compared with many other systemic immunosuppressants. Gastrointestinal distress is the most common adverse effect of the drug; additional side effects include teratogenicity and reversible cytopenias. Periodic monitoring of a complete blood count and liver and kidney function tests is recommended during treatment. (See
         <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">
          "Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"
         </a>
         .)
        </p>
        <p>
         It is unclear whether MMF leads to an increased risk for malignancy. In the retrospective study described above, one patient with a history of breast cancer developed cancer in the contralateral breast during treatment [
         <a href="#rid11">
          11
         </a>
         ]. Another patient in the study developed an Epstein Barr virus-related B cell lymphoma of the central nervous system that resolved without further intervention following the discontinuation of MMF and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         . (See
         <a class="local">
          'Efficacy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">
          "Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Neoplasia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H875202586">
         <span class="h1">
          OTHER THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data on other therapies for cutaneous DM are limited. This lack of data and/or the potential for adverse effects with many of these alternative agents generally limit their use to patients who have failed or who cannot receive other treatments for refractory disease.
        </p>
        <p class="headingAnchor" id="H3029973173">
         <span class="h2">
          Janus kinase inhibitors and traditional immunosuppressants
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are limited but increasing data suggesting benefit of newer immunosuppressant agents, the Janus kinase (JAK) inhibitors, for recalcitrant cutaneous DM. We often use these agents following intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) and/or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF) in appropriately selected patients with refractory DM.
        </p>
        <p>
         Case reports and small, uncontrolled studies suggest benefit of JAK inhibitors (eg,
         <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">
          tofacitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">
          baricitinib
         </a>
         ) [
         <a href="#rid12">
          12-17
         </a>
         ]. A systematic review of the literature published in 2022 identified a total of 61 reports of treatment of refractory cutaneous DM in adults, all documenting improvement with JAK inhibitor treatment [
         <a href="#rid18">
          18
         </a>
         ]. Examples of individual prospective studies include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an open-label study of patients with refractory DM, 11 mg of extended-release
         <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">
          tofacitinib
         </a>
         was given daily for 12 weeks following a washout of all glucocorticoid-sparing agents. All 10 patients who completed the study achieved some improvement in disease activity at 12 weeks, and this improvement was primarily driven by skin disease. The mean change in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score was statistically significant and clinically meaningful (from 28±15.4 at study entry to 9.5±8.5 at week 12) [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an open-label study in which 12 patients with cutaneous DM were treated with
         <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">
          baricitinib
         </a>
         (2 mg twice daily) for 12 weeks with or without
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and/or
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         , nine patients achieved at least a 40 percent reduction in the CDASI activity score [
         <a href="#rid16">
          16
         </a>
         ]. Pruritus (as measured by the visual analog scale itch score) also improved.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an open-label study of 16 patients with DM treated with JAK inhibitors (
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         or
         <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">
          baricitinib
         </a>
         with or without
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and/or
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         ), including 14 patients with active skin disease, the mean CDASI decreased from 27±13 at baseline to 14±11 at three months [
         <a href="#rid17">
          17
         </a>
         ]. A statistically significant change in muscle symptoms (as measured by the Manual Muscle Testing 8) was not detected.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          Azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         have also been used for the treatment of refractory noncutaneous manifestations of DM [
         <a href="#rid19">
          19-38
         </a>
         ]. Evidence for the efficacy of these agents for cutaneous disease is primarily limited to case reports and case series as documentation of clinical experience [
         <a href="#rid39">
          39-44
         </a>
         ].
        </p>
        <p>
         Safety concerns for the use of immunosuppressants include increased risk for infection and malignancy. Drug-specific safety monitoring should be performed.
        </p>
        <p class="headingAnchor" id="H9149216">
         <span class="h2">
          Rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although available data suggest
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , a biologic immunosuppressant, may be beneficial for extracutaneous manifestations of DM, studies have yielded conflicting results on the efficacy of rituximab for cutaneous manifestations. Data on the effects of rituximab on extracutaneous manifestations of DM are reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5133.html" rel="external">
          "Treatment of recurrent and resistant dermatomyositis and polymyositis in adults"
         </a>
         .)
        </p>
        <p>
         Beneficial effects of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         on the cutaneous manifestations of DM were reported in an open-label study in which seven patients with DM were treated with four weekly infusions of rituximab (100 or 375 mg/m
         <sup>
          2
         </sup>
         per infusion) [
         <a href="#rid45">
          45
         </a>
         ]. Among the five patients in whom a cutaneous eruption of DM was documented at the start of the study, all exhibited improvement in skin disease with treatment [
         <a href="#rid45">
          45
         </a>
         ]. In addition, hair regrowth occurred in two patients with alopecia secondary to DM. Treatment with rituximab was also beneficial as an adjunctive therapy in a retrospective study of juvenile DM; three out of four patients exhibited improvement in cutaneous and muscle disease [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         In contrast, an open-label study in which
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (two 1 g doses separated by two weeks) was added to the treatment regimens of eight adults with DM did not detect improvements in skin disease following treatment [
         <a href="#rid47">
          47
         </a>
         ]. Although all eight patients demonstrated sustained depletion of peripheral B cells on rituximab, a statistically significant change in the mean Dermatomyositis Skin Severity Index (DSSI) score was not detected.
        </p>
        <p>
         A posthoc analysis of data from the
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         in Myositis trial, one of the largest studies to investigate rituximab for inflammatory myositis, suggested a beneficial effect on cutaneous disease in adult and juvenile DM [
         <a href="#rid48">
          48,49
         </a>
         ]. However, lack of use of a validated cutaneous outcomes measure and lack of assessment of skin disease by dermatologists make it difficult to draw definitive conclusions from this analysis [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5133.html" rel="external">
          "Treatment of recurrent and resistant dermatomyositis and polymyositis in adults"
         </a>
         .)
        </p>
        <p>
         Additional studies using a validated skin score are necessary to determine the efficacy of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , specifically for cutaneous DM, the ideal treatment regimen, and the patient population that might benefit most from rituximab. Given limited evidence of efficacy for cutaneous DM specifically, we rarely use rituximab as treatment for DM skin disease. (See
         <a class="medical medical_review" href="/z/d/html/5133.html" rel="external">
          "Treatment of recurrent and resistant dermatomyositis and polymyositis in adults"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         usually is well tolerated. However, the drug has been associated with nausea, serum sickness-like reactions [
         <a href="#rid50">
          50
         </a>
         ], and infusion-related events, including hypotension, fevers, and rigors. In addition, a boxed warning on the drug label has been mandated by the US Food and Drug Administration (FDA) due to reports of fatalities from infusion reactions, severe mucocutaneous reactions, and progressive multifocal leukoencephalopathy due to JC virus in patients treated with rituximab. Sepsis is an uncommon complication. (See
         <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">
          "Rituximab: Principles of use and adverse effects in rheumatoid arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H157969114">
         <span class="h2">
          Dapsone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence from case reports suggests that
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         may be of benefit in cutaneous DM [
         <a href="#rid51">
          51,52
         </a>
         ]. Dapsone is usually initiated at a dose of 25 mg twice daily [
         <a href="#rid39">
          39
         </a>
         ]. The dose can be increased to a total dose of 200 to 300 mg/day when necessary.
        </p>
        <p>
         In one report, two patients with cutaneous DM unresponsive to combination therapy with
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         , quinacrine,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , and other immunosuppressive medications had rapid improvement in skin lesions with the addition of
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         [
         <a href="#rid52">
          52
         </a>
         ]. The responses to dapsone correlated with treatment; skin disease worsened upon withdrawal of dapsone and improved after reinitiation. In contrast, failures to respond to dapsone have been documented in a patient with drug-induced amyopathic DM [
         <a href="#rid53">
          53
         </a>
         ] and a patient with postmyopathic DM [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13771.html" rel="external">
          "Cutaneous dermatomyositis in adults: Overview and initial management", section on 'Amyopathic dermatomyositis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13771.html" rel="external">
          "Cutaneous dermatomyositis in adults: Overview and initial management", section on 'Postmyopathic dermatomyositis'
         </a>
         .)
        </p>
        <p>
         Hemolysis and methemoglobinemia may occur in association with
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         therapy. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at greater risk for hemolysis than the general population. Peripheral neuropathy, agranulocytosis, and a hypersensitivity syndrome are additional adverse effects of dapsone. (See
         <a class="medical medical_review" href="/z/d/html/2089.html" rel="external">
          "Drug eruptions", section on 'Drug reaction with eosinophilia and systemic symptoms'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H824939002">
         <span class="h2">
          Apremilast
         </span>
         <span class="headingEndMark">
          —
         </span>
         Findings from an open-label, phase 2a study suggest benefit of
         <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">
          apremilast
         </a>
         for cutaneous DM [
         <a href="#rid55">
          55
         </a>
         ]. Apremilast (30 mg twice daily following an initial five-day dose titration period) was added to the treatment regimen of eight patients with refractory cutaneous DM (classic, amyopathic, or juvenile). At three months, seven patients had improvement in the CDASI, with a mean decrease of 12.9 points (standard deviation 6.3 points). An analysis of skin biopsies taken before and after three months of apremilast treatment revealed downregulation of multiple inflammatory pathways. The most common adverse effects were headache, nausea, and diarrhea.
        </p>
        <p class="headingAnchor" id="H1085497323">
         <span class="h2">
          Other systemic medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other systemic agents with limited evidence for efficacy include biologic tumor necrosis factor (TNF)-alpha inhibitors,
         <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">
          leflunomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         , and antiestrogens:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biologic TNF-alpha inhibitors
         </strong>
         – Biologic TNF-alpha inhibitor therapy for cutaneous DM is generally avoided outside of monitored clinical trials. Strong evidence for the efficacy of TNF-alpha inhibitors on cutaneous DM is lacking. Most reports documenting benefit of anti-TNF therapy in DM have focused on the effects on muscle disease [
         <a href="#rid56">
          56-66
         </a>
         ]. Data on efficacy on cutaneous manifestations are sparse and contradictory, and induction or exacerbation of DM during TNF-alpha inhibitor therapy has been reported [
         <a href="#rid67">
          67-72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Moreover, the potential for adverse consequences of TNF-alpha inhibitor therapy also must be considered. It is unknown whether the baseline risk for malignancy associated with adult DM is augmented with the use of TNF-alpha inhibitors, mandating cautious use of these agents. (See
         <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">
          "Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7975.html" rel="external">
          "Tumor necrosis factor-alpha inhibitors: Risk of malignancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Leflunomide
         </strong>
         –
         <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">
          Leflunomide
         </a>
         , an immunomodulatory agent used in the treatment of rheumatoid arthritis, may be effective in some patients with cutaneous DM [
         <a href="#rid54">
          54,73
         </a>
         ]. Leflunomide led to improvements in skin disease in a series of three patients with DM refractory to multiple other systemic therapies [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thalidomide
         </strong>
         – Patients in whom cutaneous DM improved during treatment with
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         , an agent believed to exert anti-inflammatory effects through inhibition of TNF-alpha, have been reported [
         <a href="#rid53">
          53,74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiestrogens
         </strong>
         – Antiestrogens (
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         or
         <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">
          anastrozole
         </a>
         ) appeared to contribute to improvements in skin disease in two patients [
         <a href="#rid75">
          75
         </a>
         ]. The mechanism through which antiestrogens could contribute to resolution of DM is unknown; a relationship between estrogen and the production of proinflammatory cytokines, such as TNF-alpha, has been postulated [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1822005">
         <span class="h2">
          Total body irradiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Total body irradiation was associated with improvements in myositis and skin disease in two patients with refractory DM [
         <a href="#rid76">
          76
         </a>
         ]. Due to the potential for short- and long-term complications and the availability of other therapeutic options, total body irradiation generally is not recommended for the treatment of cutaneous DM.
        </p>
        <p class="headingAnchor" id="H4764538">
         <span class="h2">
          Hematopoietic stem cell transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hematopoietic stem cell transplantation has been used in the treatment of severe and refractory autoimmune diseases, including DM [
         <a href="#rid77">
          77-83
         </a>
         ]. In a child with juvenile DM, autologous peripheral hematopoietic stem cell transplantation was associated with improvements in muscle disease and the cutaneous manifestations of DM [
         <a href="#rid79">
          79
         </a>
         ]. Resolution of DM-associated calcinosis cutis has also been reported following hematopoietic stem cell transplantation [
         <a href="#rid77">
          77
         </a>
         ]. (See
         <a class="local">
          'Calcinosis cutis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H19331772">
         <span class="h1">
          CALCINOSIS CUTIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Calcinosis of the skin, soft tissues, muscle, or bone is a challenging complication of DM that is estimated to occur in at least 30 percent of patients with juvenile DM and occasionally develops in patients with adult DM. In juvenile DM, early therapeutic intervention may decrease the incidence or severity of calcinosis [
         <a href="#rid84">
          84-90
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6418.html" rel="external">
          "Juvenile dermatomyositis and polymyositis: Treatment, complications, and prognosis", section on 'Calcinosis'
         </a>
         .)
        </p>
        <p>
         Cases in which calcinosis responded to
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         , low-dose
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">
          probenecid
         </a>
         ,
         <a class="drug drug_general" data-topicid="8499" href="/z/d/drug information/8499.html" rel="external">
          aluminum hydroxide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">
          alendronate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">
          pamidronate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         , intralesional corticosteroids, intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         , topical and intralesional
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         , or electric shock wave lithotripsy have been reported [
         <a href="#rid84">
          84,91-106
         </a>
         ]. However, none of these therapies have been shown to be consistently effective for calcinosis secondary to DM. (See
         <a class="medical medical_review" href="/z/d/html/100751.html" rel="external">
          "Calcinosis cutis: Management"
         </a>
         .)
        </p>
        <p>
         Resolution of calcinosis has also been reported in patients receiving treatment for DM with
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         or hematopoietic stem cell transplantation [
         <a href="#rid62">
          62,77,107,108
         </a>
         ]. Typically, smaller and more recently deposited calcinotic nodules respond more readily than long-standing, large plaques. Surgical excision can be used to remove cutaneous or subcutaneous lesions that are symptomatic and unresponsive to medical therapy [
         <a href="#rid109">
          109
         </a>
         ]. Occasionally, calcinosis cutis regresses spontaneously [
         <a href="#rid106">
          106
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/100751.html" rel="external">
          "Calcinosis cutis: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3684459754">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114586.html" rel="external">
          "Society guideline links: Dermatomyositis and polymyositis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19331779">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Dermatomyositis (DM) is an idiopathic inflammatory disorder that is associated with a set of characteristic cutaneous findings. Patients who fail to respond to conventional therapies or who experience recurrence of disease with standard therapies require more aggressive immunosuppressive or immunomodulatory therapies for disease control  (
         <a class="graphic graphic_algorithm graphicRef119738" href="/z/d/graphic/119738.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Approach to refractory disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/13771.html" rel="external">
          "Cutaneous dermatomyositis in adults: Overview and initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary therapies
         </strong>
         – Data are limited on treatments for refractory cutaneous DM. The limited efficacy data and concerns over drug safety, tolerability, and cost influence the selection of the most appropriate therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with cutaneous manifestations of DM that are refractory to topical therapies, antimalarials, and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , we suggest treatment with intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF) based on evidence that suggests efficacy and the relative safety of these drugs (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Primary therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other therapies
         </strong>
         – Limited data suggest that oral Janus kinase (JAK) inhibitors may be beneficial for select patients with refractory cutaneous DM. (See
         <a class="local">
          'Janus kinase inhibitors and traditional immunosuppressants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other therapies used for refractory cutaneous DM include immunosuppressive agents (eg,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         , and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ),
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         , and
         <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">
          apremilast
         </a>
         . A lack of strong evidence in support of these therapies or risks of serious adverse effects associated with many of these therapies generally relegate use to patients who have failed or cannot receive
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         and MMF. (See
         <a class="local">
          'Other therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calcinosis cutis
         </strong>
         – Calcinosis cutis is a common cutaneous manifestation in patients with juvenile DM. Although a variety of agents have been used for this indication, none have shown consistent benefit. (See
         <a class="local">
          'Calcinosis cutis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329:1993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aggarwal R, Charles-Schoeman C, Schessl J, et al. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med 2022; 387:1264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peake MF, Perkins P, Elston DM, et al. Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin. Cutis 1998; 62:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbasso Helmers S, Dastmalchi M, Alexanderson H, et al. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis 2007; 66:1276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadayama T, Miyagawa S, Shirai T. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. J Dermatol 1999; 26:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Femia AN, Eastham AB, Lam C, et al. Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center. J Am Acad Dermatol 2013; 69:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bounfour T, Bouaziz JD, Bézier M, et al. Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease. J Eur Acad Dermatol Venereol 2014; 28:1150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolstencroft PW, Chung L, Li S, et al. Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis. JAMA Dermatol 2018; 154:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tausche AK, Meurer M. Mycophenolate mofetil for dermatomyositis. Dermatology 2001; 202:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 2000; 27:1542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006; 142:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hornung T, Janzen V, Heidgen FJ, et al. Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med 2014; 371:2537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurtzman DJ, Wright NA, Lin J, et al. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment. JAMA Dermatol 2016; 152:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paik JJ, Casciola-Rosen L, Shin JY, et al. Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients. Arthritis Rheumatol 2021; 73:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Min MS, Alsarheed A, Kassamali B, et al. Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers. J Am Acad Dermatol 2022; 86:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao Q, Zhu Z, Fu Q, et al. Baricitinib for the treatment of cutaneous dermatomyositis: A prospective, open-label study. J Am Acad Dermatol 2022; 87:1374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landon-Cardinal O, Guillaume-Jugnot P, Toquet S, et al. JAK inhibitors for the treatment of adult dermatomyositis: A pilot study. J Am Acad Dermatol 2023; 88:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paik JJ, Lubin G, Gromatzky A, et al. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review. Clin Exp Rheumatol 2023; 41:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lueck CJ, Trend P, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry 1991; 54:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grau JM, Herrero C, Casademont J, et al. Cyclosporine A as first choice therapy for dermatomyositis. J Rheumatol 1994; 21:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 2000; 27:2855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vencovský J, Jarosová K, Machácek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000; 29:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997; 24:2436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heckmatt J, Hasson N, Saunders C, et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; 1:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HJ, Hong YK, Yoo WH. Dermatomyositis, complicated with pneumomediastinum, successfully treated with cyclosporine A: a case report and review of literature. Rheumatol Int 2009; 29:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ochi S, Nanki T, Takada K, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol 2005; 23:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52:2439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ando M, Miyazaki E, Yamasue M, et al. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol 2010; 29:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitsui T, Kuroda Y, Kunishige M, Matsumoto T. Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med 2005; 44:1197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mok CC, To CH, Szeto ML. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand J Rheumatol 2003; 32:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer O, Hayem G, Palazzo E, et al. Interstitial lung disease due to polymyositis or dermatomyositis: effect of a 6-month course of i.v. pulse cyclophosphamide. Clin Exp Rheumatol 2005; 23:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takashi S, Okubo Y, Yamazaki Y, et al. [Amyopathic dermatomyositis with interstitial pneumonia: effective treatment with cyclophosphamide pulse therapy]. Nihon Kokyuki Gakkai Zasshi 1999; 37:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007; 46:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinoway PA, Callen JP. Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993; 36:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cagnoli M, Marchesoni A, Tosi S. Combined steroid, methotrexate and chlorambucil therapy for steroid-resistant dermatomyositis. Clin Exp Rheumatol 1991; 9:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace DJ, Metzger AL, White KK. Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis. Arthritis Rheum 1985; 28:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nadiminti U, Arbiser JL. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol 2005; 52:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaposztas Z, Etheridge WB, Kahan BD. Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus. Transplant Proc 2008; 40:1744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sontheimer RD. The management of dermatomyositis: current treatment options. Expert Opin Pharmacother 2004; 5:1083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsujimura S, Saito K, Tanaka Y. Complete resolution of dermatomyositis with refractory cutaneous vasculitis by intravenous cyclophosphamide pulse therapy. Intern Med 2008; 47:1935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 2008; 27:1469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martín Nalda A, Modesto Caballero C, Arnal Guimeral C, et al. [Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases]. Med Clin (Barc) 2006; 127:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada A, Ohshima Y, Omata N, et al. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur J Pediatr 2004; 163:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimojima Y, Ishii W, Kato T, et al. Intractable skin necrosis and interstitial pneumonia in amyopathic dermatomyositis, successfully treated with cyclosporin A. Intern Med 2003; 42:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper MA, Willingham DL, Brown DE, et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007; 56:3107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007; 143:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aggarwal R, Loganathan P, Koontz D, et al. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford) 2017; 56:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003; 14:1792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konohana A, Kawashima J. Successful treatment of dermatomyositis with dapsone. Clin Exp Dermatol 1994; 19:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen JB. Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. Int J Dermatol 2002; 41:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flores-Suárez LF, Morales H, Angeles A, Kraus A. Drug-induced amyopathic dermatomyositis. J Clin Rheumatol 2002; 8:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol 2008; 58:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bitar C, Ninh T, Brag K, et al. Apremilast in Recalcitrant Cutaneous Dermatomyositis: A Nonrandomized Controlled Trial. JAMA Dermatol 2022; 158:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hengstman G, van den Hoogen, van Engelen B, et al. Anti-TNF blockade with infliximab (Remicade) in polymyositis and dermatomyositis. Arthritis Rheum 2000; 43:S193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 2006; 54:S139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selva-O'Callaghan A, Martínez-Costa X, Solans-Laque R, et al. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford) 2004; 43:1196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford) 2004; 43:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korkmaz C, Temiz G, Cetinbas F, Büyükkidan B. Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha. Rheumatology (Oxford) 2004; 43:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006; 65:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008; 47:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller M, Mendez E, Klein-Gitelman M. Use of etanercept in juvenile dermatomyositis. Arthritis Rheum 2002; 46:S306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saddeh CK. Entanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy including steroids and other disease modifying agents. Arthritis Rheum 2000; 43:S193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nzeusseu A, Durez P, Houssiau H, Devogelaer J. Successful use of infliximab in a case of refractory juvenile dermatomyositis. Arthritis Rheum 2000; 43:S193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dold S, Justiniano ME, Marquez J, Espinoza LR. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 2007; 26:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67:1670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iannone F, Scioscia C, Falappone PC, et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006; 33:1802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hengstman GJ, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008; 59:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005; 7:R666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2006; 55:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010; 146:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sangle VS, Sangle SR, D'Cruz DP. Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann Rheum Dis 2008; 67:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sebastiani M, Puccini R, Manfredi A, et al. Staphylococcus protein A-based extracorporeal immunoadsorption and thalidomide in the treatment of skin manifestation of dermatomyositis: a case report. Ther Apher Dial 2009; 13:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sereda D, Werth VP. Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol 2006; 142:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly JJ, Madoc-Jones H, Adelman LS, et al. Response to total body irradiation in dermatomyositis. Muscle Nerve 1988; 11:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holzer U, van Royen-Kerkhof A, van der Torre P, et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 2010; 39:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saccardi R, Di Gioia M, Bosi A. Haematopoietic stem cell transplantation for autoimmune disorders. Curr Opin Hematol 2008; 15:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu FQ, Luan Z, Lai JM, et al. [Treatment of refractory rheumatism among preschool children with autologous peripheral blood hematopoietic stem cell transplantation]. Zhonghua Er Ke Za Zhi 2007; 45:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oryoji K, Himeji D, Nagafuji K, et al. Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis. Clin Rheumatol 2005; 24:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsukamoto H, Nagafuji K, Horiuchi T, et al. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis 2006; 65:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006; 45:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tyndall A, Passweg J, Gratwohl A. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann Rheum Dis 2001; 60:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pachman LM. Juvenile dermatomyositis: decreased calcinosis with intermittent high-dose intravenous methylprednisolone therapy. Arthritis Rheum 1994; 37:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisler RE, Liang MG, Fuhlbrigge RC, et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002; 47:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pachman LM, Hayford JR, Chung A, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998; 25:1198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller LC, Michael AF, Kim Y. Childhood dermatomyositis. Clinical course and long-term follow-up. Clin Pediatr (Phila) 1987; 26:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shehata R, al-Mayouf S, al-Dalaan A, et al. Juvenile dermatomyositis: clinical profile and disease course in 25 patients. Clin Exp Rheumatol 1999; 17:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 2000; 19:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahani L. Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin. BMJ Case Rep 2012; 2012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuoka Y, Miyajima S, Okada N. A case of calcinosis universalis successfully treated with low-dose warfarin. J Dermatol 1998; 25:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harel L, Harel G, Korenreich L, et al. Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. J Rheumatol 2001; 28:1129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang WJ, Lo WL, Wong CK. Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminum hydroxide therapy. Arch Dermatol 1988; 124:1721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 2001; 138:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambler GR, Chaitow J, Rogers M, et al. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 2005; 32:1837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downey EC Jr, Woolley MM, Hanson V. Required surgical therapy in the pediatric patient with dermatomyositis. Arch Surg 1988; 123:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu JJ, Metz BJ. Calcinosis cutis of juvenile dermatomyositis treated with incision and drainage. Dermatol Surg 2008; 34:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan AY, Li E. Electric shock wave lithotripsy (ESWL) as a pain control measure in dermatomyositis with calcinosis cutis-old method, new discovery. Clin Rheumatol 2005; 24:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdallah-Lotf M, Grasland A, Vinceneux P, Sigal-Grinberg M. Regression of cutis calcinosis with diltiazem in adult dermatomyositis. Eur J Dermatol 2005; 15:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliveri MB, Palermo R, Mautalen C, Hübscher O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol 1996; 23:2152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinen CS, Patel S, Bruckner FE. Regression of calcinosis associated with adult dermatomyositis following diltiazem therapy. Rheumatology (Oxford) 2000; 39:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marco Puche A, Calvo Penades I, Lopez Montesinos B. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 2010; 28:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 2010; 77:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs D, Fruchter L, Fishel B, et al. Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol 1986; 5:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Mayouf SM, Alsonbul A, Alismail K. Localized calcinosis in juvenile dermatomyositis: successful treatment with intralesional corticosteroids injection. Int J Rheum Dis 2010; 13:e26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schanz S, Ulmer A, Fierlbeck G. Response of dystrophic calcification to intravenous immunoglobulin. Arch Dermatol 2008; 144:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peñate Y, Guillermo N, Melwani P, et al. Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin. J Am Acad Dermatol 2009; 60:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shearin JC, Pickrell K. Surgical treatment of subcutaneous calcifications of polymyositis or dermatomyositis. Ann Plast Surg 1980; 5:381.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13774 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8247075" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36198179" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Trial of Intravenous Immune Globulin in Dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9714905" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17277004" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10458087" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24034377" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23906502" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29114741" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11455153" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Mycophenolate mofetil for dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10852287" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16415388" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25539124" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Remission of recalcitrant dermatomyositis treated with ruxolitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27120749" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33258553" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34246697" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35998841" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Baricitinib for the treatment of cutaneous dermatomyositis: A prospective, open-label study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36356704" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : JAK inhibitors for the treatment of adult dermatomyositis: A pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35766013" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1800644" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cyclosporin in the management of polymyositis and dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8182665" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Cyclosporine A as first choice therapy for dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11128676" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10777122" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9415655" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2566009" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Cyclosporin in juvenile dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19093116" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Dermatomyositis, complicated with pneumomediastinum, successfully treated with cyclosporine A: a case report and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16173253" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16052580" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20130943" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16357462" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Successful treatment with tacrolimus in a case of refractory dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12892257" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16173257" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Interstitial lung disease due to polymyositis or dermatomyositis: effect of a 6-month course of i.v. pulse cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10496106" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : [Amyopathic dermatomyositis with interstitial pneumonia: effective treatment with cyclophosphamide pulse therapy].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16754626" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8452575" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1764849" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Combined steroid, methotrexate and chlorambucil therapy for steroid-resistant dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4004968" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15692505" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18589184" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15155110" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The management of dermatomyositis: current treatment options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18981641" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Complete resolution of dermatomyositis with refractory cutaneous vasculitis by intravenous cyclophosphamide pulse therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18716733" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Treatment of refractory juvenile dermatomyositis with tacrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17169297" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : [Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15243811" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14714970" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Intractable skin necrosis and interstitial pneumonia in amyopathic dermatomyositis, successfully treated with cyclosporin A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15692974" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Rituximab in the treatment of dermatomyositis: an open-label pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17763414" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17576943" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A pilot trial of rituximab in the treatment of patients with dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23124935" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27837048" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14630688" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7955489" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Successful treatment of dermatomyositis with dapsone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12010348" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Cutaneous involvement of dermatomyositis can respond to Dapsone therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17039201" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Drug-induced amyopathic dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18194823" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Leflunomide as adjuvant treatment of dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36197661" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Apremilast in Recalcitrant Cutaneous Dermatomyositis: A Nonrandomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Anti-TNF blockade with infliximab (Remicade) in polymyositis and dermatomyositis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16488329" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Case reports of etanercept in inflammatory dermatoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15317960" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15024139" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15213343" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16476710" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18403404" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Use of etanercept in juvenile dermatomyositis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Entanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy including steroids and other disease modifying agents
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Successful use of infliximab in a case of refractory juvenile dermatomyositis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16736125" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Treatment of early and refractory dermatomyositis with infliximab: a report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18272672" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16960940" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Use of etanercept in the treatment of dermatomyositis: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18230873" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15899052" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17139649" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20644041" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Tumor necrosis factor inhibitor-associated dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18408111" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19527470" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Staphylococcus protein A-based extracorporeal immunoadsorption and thalidomide in the treatment of skin manifestation of dermatomyositis: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16415389" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Improvement in dermatomyositis rash associated with the use of antiestrogen medication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3278219" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Response to total body irradiation in dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20132077" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18832930" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Haematopoietic stem cell transplantation for autoimmune disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18282409" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : [Treatment of refractory rheumatism among preschool children with autologous peripheral blood hematopoietic stem cell transplantation].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15902522" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16126798" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16777856" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Adult stem cells in the treatment of autoimmune diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11406528" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Juvenile dermatomyositis: decreased calcinosis with intermittent high-dose intravenous methylprednisolone therapy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12271292" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6644423" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9632086" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3665326" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Childhood dermatomyositis. Clinical course and long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10084045" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Juvenile dermatomyositis: clinical profile and disease course in 25 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10791626" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22907859" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9863284" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : A case of calcinosis universalis successfully treated with low-dose warfarin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11361202" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3178257" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminum hydroxide therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11343059" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16142885" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3415463" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Required surgical therapy in the pediatric patient with dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18248486" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Calcinosis cutis of juvenile dermatomyositis treated with incision and drainage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15565396" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Electric shock wave lithotripsy (ESWL) as a pain control measure in dermatomyositis with calcinosis cutis-old method, new discovery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15757822" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Regression of cutis calcinosis with diltiazem in adult dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8970055" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10788545" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Regression of calcinosis associated with adult dermatomyositis following diltiazem therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20346254" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20031471" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3816102" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20704606" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Localized calcinosis in juvenile dermatomyositis: successful treatment with intralesional corticosteroids injection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18490584" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Response of dystrophic calcification to intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19467386" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7458175" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Surgical treatment of subcutaneous calcifications of polymyositis or dermatomyositis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
